Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nader Tobia

Internal Medicine Park Forest, IL Medical Doctor

NPI 1831175447 CMS profile 128508

114 N Orchard Dr, Park Forest, IL 60466

Open in the dashboard

General payments

$10,572

624 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nader Tobia of Park Forest, IL is reported in the CMS Open Payments database as having received $10,572 across 624 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,307 74
2024 General $1,646 96
2023 General $1,946 118
2022 General $1,576 99
2021 General $1,726 117
2020 General $879 56
2019 General $1,493 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nader Tobia
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nader Tobia were reported at $1,307. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nader Tobia Internal Medicine median Middle half National median
2019 $1,493 $159 $48–$570 $163
2020 $879 $119 $33–$402 $114
2021 $1,726 $135 $37–$521 $132
2022 $1,576 $141 $42–$496 $149
2023 $1,946 $149 $45–$519 $160
2024 $1,646 $154 $47–$537 $164
2025 $1,307 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,864 100 payments
  2. GlaxoSmithKline, LLC. $1,303 99 payments
  3. Lilly USA, LLC $1,256 77 payments
  4. Janssen Pharmaceuticals, Inc $967 30 payments
  5. AbbVie, Inc. $619 46 payments
  6. Pfizer Inc. $548 29 payments
  7. Novartis Pharmaceuticals Corporation $483 32 payments
  8. Merck Sharp & Dohme Corporation $446 27 payments
  9. Novo Nordisk Inc $385 24 payments
  10. Amarin Pharma Inc. $279 20 payments
  11. Other $2,421 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,532 619 payments
  2. Education $40 5 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,210 91 payments
  2. MOUNJARO $729 44 payments
  3. XARELTO $682 24 payments
  4. BREZTRI $670 36 payments
  5. FARXIGA $614 25 payments
  6. VERQUVO $530 32 payments
  7. JARDIANCE $471 29 payments
  8. AIRSUPRA $433 18 payments
  9. ELIQUIS $400 21 payments
  10. ENTRESTO $383 26 payments
  11. Other $7,400 453 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 189 drugs

Part D claims

15,042

Median for Internal Medicine: 777

Drug cost

$2,091,263

Median for Internal Medicine: $73,373

Branded share of claims

28.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 369 $495,062
Eliquis Apixaban Brand 253 $262,758
Mounjaro Tirzepatide Brand 151 $163,260
Farxiga Dapagliflozin Propanediol Brand 138 $161,392
Ozempic Semaglutide Brand 135 $147,544
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 150 $134,648
Entresto Sacubitril/Valsartan Brand 80 $81,352
Trulicity Dulaglutide Brand 66 $73,573
Linzess Linaclotide Brand 60 $57,078
Tresiba Flextouch U-200 Insulin Degludec Brand 39 $36,488

The 10 drugs with the highest cost, of 189 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$342,259

Of which drugs: $3,717

Medicare patients

601

Average age 75

Services billed

5,479

326 women, 275 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 55%
Arthritis 43%
Chronic kidney disease 37%
Ischemic heart disease 33%
Heart failure 27%
Atrial fibrillation 26%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 141 141 $3,088
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 111 316 $291
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90688 Office 11 11 $225
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 51 $31
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 32 $18
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 Office 12 15 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$194 — —
FARXIGA
$188 138 —
TRELEGY ELLIPTA
$174 150 —
MOUNJARO
$114 151 —
VERQUVO
$110 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

624 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record